hotspot -WSS

hotspot

author：knowledge 2025-09-27 21:55:03 - browse：5216

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Blood tests recalled over risk of missed heart attack diagnosis

WSS

Creating egg and sperm cells from stem cells raises ethical issues

Grail faces three suits alleging harassment, retaliation

Europe sees delivery challenges ahead on Alzheimer's therapies

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Federal judge rules Oregon’s tough new gun law is constitutional

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Apple is now the first public company to be valued at $3 trillion

Congress likely to miss an opportunity to fix drug shortages issue

Drug repurposing or repositioning? The language matters

Positive childhood experiences can help future health

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Baby aspirin cuts fat buildup in liver disease patients, in small study

Medical leaders decry Supreme Court decision on affirmative action

Everything to know for the next Powerball drawing as jackpot hits $1 billion

knowledge

Celiac disease study examines precisely how gluten triggers injury

Future doctors should be trained to promote social change

Neuroscience’s long legacy of racism

Argenx drug significantly slows progression of nerve disorder

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Who gets to use the title 'doctor'?

entertainment

knowledge

knowledge

explore